First Time Loading...

Celldex Therapeutics Inc
NASDAQ:CLDX

Watchlist Manager
Celldex Therapeutics Inc Logo
Celldex Therapeutics Inc
NASDAQ:CLDX
Watchlist
Price: 37.98 USD -1.43% Market Closed
Updated: Apr 20, 2024

Intrinsic Value

CLDX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. [ Read More ]

The intrinsic value of one CLDX stock under the Base Case scenario is 0.6 USD. Compared to the current market price of 37.98 USD, Celldex Therapeutics Inc is Overvalued by 98%.

Key Points:
CLDX Intrinsic Value
Base Case
0.6 USD
Overvaluation 98%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Celldex Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling CLDX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Celldex Therapeutics Inc

Provide an overview of the primary business activities
of Celldex Therapeutics Inc.

What unique competitive advantages
does Celldex Therapeutics Inc hold over its rivals?

What risks and challenges
does Celldex Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Celldex Therapeutics Inc recently?

Summarize the latest earnings call
of Celldex Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Celldex Therapeutics Inc.

Provide P/S
for Celldex Therapeutics Inc.

Provide P/E
for Celldex Therapeutics Inc.

Provide P/OCF
for Celldex Therapeutics Inc.

Provide P/FCFE
for Celldex Therapeutics Inc.

Provide P/B
for Celldex Therapeutics Inc.

Provide EV/S
for Celldex Therapeutics Inc.

Provide EV/GP
for Celldex Therapeutics Inc.

Provide EV/EBITDA
for Celldex Therapeutics Inc.

Provide EV/EBIT
for Celldex Therapeutics Inc.

Provide EV/OCF
for Celldex Therapeutics Inc.

Provide EV/FCFF
for Celldex Therapeutics Inc.

Provide EV/IC
for Celldex Therapeutics Inc.

Show me price targets
for Celldex Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Celldex Therapeutics Inc?

How accurate were the past Revenue estimates
for Celldex Therapeutics Inc?

What are the Net Income projections
for Celldex Therapeutics Inc?

How accurate were the past Net Income estimates
for Celldex Therapeutics Inc?

What are the EPS projections
for Celldex Therapeutics Inc?

How accurate were the past EPS estimates
for Celldex Therapeutics Inc?

What are the EBIT projections
for Celldex Therapeutics Inc?

How accurate were the past EBIT estimates
for Celldex Therapeutics Inc?

Compare the revenue forecasts
for Celldex Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Celldex Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Celldex Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Celldex Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Celldex Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Celldex Therapeutics Inc with its peers.

Analyze the financial leverage
of Celldex Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Celldex Therapeutics Inc.

Provide ROE
for Celldex Therapeutics Inc.

Provide ROA
for Celldex Therapeutics Inc.

Provide ROIC
for Celldex Therapeutics Inc.

Provide ROCE
for Celldex Therapeutics Inc.

Provide Gross Margin
for Celldex Therapeutics Inc.

Provide Operating Margin
for Celldex Therapeutics Inc.

Provide Net Margin
for Celldex Therapeutics Inc.

Provide FCF Margin
for Celldex Therapeutics Inc.

Show all solvency ratios
for Celldex Therapeutics Inc.

Provide D/E Ratio
for Celldex Therapeutics Inc.

Provide D/A Ratio
for Celldex Therapeutics Inc.

Provide Interest Coverage Ratio
for Celldex Therapeutics Inc.

Provide Altman Z-Score Ratio
for Celldex Therapeutics Inc.

Provide Quick Ratio
for Celldex Therapeutics Inc.

Provide Current Ratio
for Celldex Therapeutics Inc.

Provide Cash Ratio
for Celldex Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Celldex Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Celldex Therapeutics Inc?

What is the current Free Cash Flow
of Celldex Therapeutics Inc?

Financials

Balance Sheet Decomposition
Celldex Therapeutics Inc

Current Assets 431.7m
Cash & Short-Term Investments 423.6m
Receivables 2.6m
Other Current Assets 5.5m
Non-Current Assets 33.9m
PP&E 6.6m
Intangibles 27.2m
Other Non-Current Assets 107k
Current Liabilities 31.1m
Accounts Payable 3.5m
Accrued Liabilities 23.6m
Other Current Liabilities 4m
Non-Current Liabilities 5.3m
Other Non-Current Liabilities 5.3m
Efficiency

Earnings Waterfall
Celldex Therapeutics Inc

Revenue
6.9m USD
Operating Expenses
-148.9m USD
Operating Income
-142m USD
Other Expenses
613k USD
Net Income
-141.4m USD

Free Cash Flow Analysis
Celldex Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

CLDX Profitability Score
Profitability Due Diligence

Celldex Therapeutics Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.

Exceptional 1-Year Revenue Growth
ROE is Increasing
Negative 3-Years Revenue Growth
Declining ROIC
17/100
Profitability
Score

Celldex Therapeutics Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.

CLDX Solvency Score
Solvency Due Diligence

Celldex Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Celldex Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CLDX Price Targets Summary
Celldex Therapeutics Inc

Wall Street analysts forecast CLDX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CLDX is 72.13 USD with a low forecast of 35.35 USD and a high forecast of 94.5 USD.

Lowest
Price Target
35.35 USD
7% Downside
Average
Price Target
72.13 USD
90% Upside
Highest
Price Target
94.5 USD
149% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

CLDX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

CLDX Price
Celldex Therapeutics Inc

1M 1M
-10%
6M 6M
+55%
1Y 1Y
+6%
3Y 3Y
+60%
5Y 5Y
+949%
10Y 10Y
-83%
Annual Price Range
37.98
52w Low
22.61
52w High
51.88
Price Metrics
Average Annual Return 206.73%
Standard Deviation of Annual Returns 366.28%
Max Drawdown -64%
Shares Statistics
Market Capitalization 2.5B USD
Shares Outstanding 65 698 700
Percentage of Shares Shorted 11.44%

CLDX Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Celldex Therapeutics Inc Logo
Celldex Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

2.5B USD

Dividend Yield

0%

Description

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. The company is headquartered in Hampton, New Jersey and currently employs 132 full-time employees. The firm is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. The firm is using the technologies to develop targeted immunotherapeutics consisting of protein-based molecules, such as vaccines, antibodies and antibody-drug conjugates that are used to treat specific types of cancer or other diseases. The company operates in development, manufacturing of therapeutics. Company's CDX-0159, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity. Its CDX-1140, an agonist monoclonal antibody targeted to CD40, a key activator of immune response, being studied in a Phase II study. The firm's CDX-527, a bispecific antibody that uses active anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway, for which it initiated a Phase II study in advanced solid tumors.

Contact

NEW JERSEY
Hampton
53 Frontage Rd Ste 220
+19082007500.0
http://www.celldex.com/

IPO

1986-05-15

Employees

132

Officers

Founder, President, CEO & Director
Mr. Anthony S. Marucci M.B.A.
Founder, Chief Scientific Officer & Executive VP
Dr. Tibor Keler
Senior VP, CFO, Secretary & Treasurer
Mr. Sam Martin
Senior Vice President of Regulatory Affairs
Dr. Margo Heath-Chiozzi M.D.
Senior VP & Chief Medical Officer
Dr. Diane C. Young M.D.
Co-Founder & Member of Scientific Advisory Board
Prof. Joseph P. Schlessinger Ph.D.
Show More
Senior Vice President of Corporate Affairs & Administration
Ms. Sarah Cavanaugh
Senior Director of Investor Relations & Corporate Communications
Patrick Till
Senior VP & General Counsel
Mr. Freddy A. Jimenez Esq.
Chief Business Officer & Senior VP
Dr. Ronald A. Pepin
Show Less

See Also

Discover More
What is the Intrinsic Value of one CLDX stock?

The intrinsic value of one CLDX stock under the Base Case scenario is 0.6 USD.

Is CLDX stock undervalued or overvalued?

Compared to the current market price of 37.98 USD, Celldex Therapeutics Inc is Overvalued by 98%.